Participant flow

Arsenic Trioxide and Gemtuzumab Ozogamicin in Treating Patients With Advanced Myelodysplastic Syndromes · Source last updated 2015-07-10

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

groups

1. description

   ATO dosing was based on the phase 2 European Union regimen at a dose of 0.25 mg/kg administered intravenously on Days 1 through 5 during Week 1 and then twice weekly during Weeks 2 to 12, and GO at a dose of 3mg/m2 on Day 8 for 1 or 2 cycles of 12 weeks each.

   id

   FG000

   title

   ATO (0.25mg/kg) and GO (3mg/m2)

periods

1. milestones

   1. achievements

      1. group Id

         FG000

         num Subjects

         30

      type

      STARTED

   2. achievements

      1. group Id

         FG000

         num Subjects

         30

      type

      COMPLETED

   3. achievements

      1. group Id

         FG000

         num Subjects

         0

      type

      NOT COMPLETED

   title

   Overall Study

recruitment Details

Patients were enrolled at Cleveland Clinic and the University of Michigan from February 2004 through June 2006.

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice